Excision BioTherapeutics

Excision BioTherapeutics is a clinical-stage biotechnology company focused on developing CRISPR-based therapies to cure serious latent viral infectious diseases. Their proprietary multiplexed gene editing platform utilizes next-generation CRISPR nucleases and a novel gene editing approach to develop curative treatments. The company's pipeline is focused on large, underserved markets including herpes simplex virus-1 keratitis (HSV-1 keratitis), hepatitis B virus (HBV), and human immunodeficiency virus-1 (HIV-1). They are committed to improving the lives of chronically ill patients by excising viral genomes from infected individuals.

Excision BioTherapeutics was founded in 2015 and is headquartered in Watertown, MA. Their foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at the University of California, Berkeley. Excision has a team of dedicated experts in molecular biology, regulatory management, and clinical development, working together to bring life-changing therapies to patients.

Excision BioTherapeutics offers employees flexible paid time off, comprehensive benefits including health, dental, and vision coverage, life and disability insurance, and a 401k matching program. They also provide employees with the equipment they need to work comfortably, such as laptops and monitors.

Excision BioTherapeutics offers a comprehensive benefits package that includes 100% coverage for health, dental, and vision for employees and their dependents, as well as generous life and disability insurance programs. Additionally, they provide a 401(k) matching plan to help employees save for their future. To ensure a comfortable work environment, they provide the necessary equipment, including laptops, monitors, and any additional tools needed. Finally, they offer flexible PTO to encourage employees to take time off to recharge and care for themselves.

Excision BioTherapeutics is a biotechnology company dedicated to developing CRISPR-based therapies as potential cures for serious latent viral infectious diseases. They are pioneering a treatment modality that targets and inactivates viral DNA, focusing on diseases like herpes simplex virus-1 keratitis, hepatitis B virus, and human immunodeficiency virus-1. Their mission is to improve the lives of chronically ill patients by developing transformative therapies that eliminate viral genomes from infected individuals, ultimately offering hope for a cure.

Excision BioTherapeutics cultivates a collaborative and results-oriented culture, driven by a shared mission to cure viral infectious diseases. They value innovation and scientific excellence, empowering their team of experts in molecular biology, regulatory management, and clinical development to push boundaries and achieve impactful outcomes. The company fosters a supportive environment with flexible PTO, comprehensive benefits, and opportunities for personal and professional growth.

Excision BioTherapeutics is committed to fostering a diverse, equitable, and inclusive workplace that values and celebrates the unique perspectives and experiences of its employees. The company prioritizes building a culture where everyone feels respected, supported, and empowered to contribute their best work. Excision is dedicated to attracting, retaining, and promoting a diverse workforce by creating a welcoming environment that reflects the diverse communities it serves.